Leqvio Month-by-Month: What to Expect in the First 3 Months

How Inclisiran Works and Why the Timeline Matters

Inclisiran is a small-interfering RNA (siRNA) that silences the gene encoding PCSK9 inside hepatocytes. Unlike monoclonal antibody PCSK9 inhibitors such as evolocumab or alirocumab, it does not neutralize circulating PCSK9 protein; it stops the liver from producing the protein in the first place. That mechanistic difference shapes the entire month-by-month experience: the drug builds effect over weeks as existing PCSK9 mRNA is degraded, and the effect is sustained for months because the silencing outlasts the drug's plasma half-life.

The FDA approved inclisiran on December 22, 2021, under NDA 214016, for adults with primary hypercholesterolaemia or mixed dyslipidaemia as an adjunct to diet and maximally tolerated statin therapy. See the FDA label at accessdata.fda.gov.

The Standard Dosing Schedule

The approved schedule is a 284 mg subcutaneous injection on day 1, a second injection on day 90 (month 3), then one injection every 6 months. The day-90 injection is timed specifically to catch LDL-C before it begins to drift back toward baseline. Patients who miss the day-90 window by more than 3 months should contact their prescriber because the 6-month maintenance schedule resets from the date of the actual second dose.

Why Labs Matter More Than Symptoms

Inclisiran has no perceptible pharmacological effect. There is no flushing, no muscle signal, no energy change. For most patients, the only evidence that anything happened in months 1 through 3 is a lipid panel drawn at or around week 12. That single data point carries clinical weight: it tells the prescribing team whether the day-90 second dose is on track and whether additional background therapy adjustments are needed.

Month 1 (Days 1 to 30): The Injection and the Early Drop

What Happens at the Injection Appointment

The first Leqvio injection is given in a clinic, physician's office, or pharmacy setting by a trained provider. The injection volume is 1.5 mL, delivered subcutaneously into the abdomen, upper arm, or thigh. The visit itself typically takes under 15 minutes.

The ORION-10 trial (N=1,561, patients with atherosclerotic cardiovascular disease) reported injection-site reactions in 2.6% of inclisiran recipients versus 0.9% of placebo recipients. ORION-10, published in the New England Journal of Medicine, 2020. Reactions were almost entirely mild: redness, transient pain, or a small nodule at the injection site. None led to trial discontinuation.

LDL-C Trajectory in Week 1 Through Week 4

Measurable LDL-C reduction appears by day 14 in pharmacokinetic-pharmacodynamic modeling from the phase 1 and phase 2 ORION program. By day 30, most patients see a 25 to 35% reduction from baseline in clinical trial data. The ORION-1 phase 2 dose-finding trial (N=501) demonstrated dose-dependent LDL-C lowering beginning within 2 weeks.

Real-world patient accounts on Reddit's r/familialcholesterol and r/Cholesterol forums echo this timeline. A recurring theme: patients who check their lipid panel at the 4-week mark are often surprised at how large the early drop is, particularly because they feel nothing different.

What to Do in Month 1

• Continue all background statin and ezetimibe therapy as prescribed.
• Do not schedule a lipid panel before week 8; values at week 2 or 4 underestimate the eventual steady-state reduction.
• Report any injection-site changes (warmth, increasing size) that persist beyond 5 days, though this is uncommon.

Month 2 (Days 31 to 60): The Reduction Deepens

By week 8, the siRNA-mediated suppression of PCSK9 mRNA is near its nadir for the first dose cycle. In the pooled ORION-9, ORION-10, and ORION-11 trials, inclisiran produced a time-averaged LDL-C reduction of approximately 50% from baseline at the day-90 assessment point, which reflects values accrued across months 2 and 3. The pooled ORION results (total N=3,660) were published in the Journal of the American College of Cardiology.

Patient-Reported Experience at Week 8

Patients who share progress online typically describe month 2 as uneventful in the best possible way. LDL-C values, when checked, are often the lowest the patient has seen in years. Muscle aches reported during this period are generally attributable to background statin therapy, not inclisiran. The ORION trials found no statistically significant increase in myalgia with inclisiran versus placebo when statin doses were held constant.

Monitoring in Month 2

No clinic visit is required between the day-1 injection and the day-90 second dose unless the patient develops symptoms. A fasting lipid panel at week 8 is optional but gives useful baseline data before the second injection. ACC/AHA guidelines recommend repeating a lipid panel 4 to 12 weeks after starting or adjusting any LDL-C-lowering therapy. ACC/AHA 2018 Guideline on the Management of Blood Cholesterol, published in Circulation.

Month 3 (Days 61 to 90): The Second Injection and What Lab Values Show

LDL-C at Day 90

Day 90 is both a measurement milestone and a treatment day. Before giving the second injection, most providers draw a fasting lipid panel. In the ORION-11 trial (N=1,617, European patients with high cardiovascular risk), mean LDL-C had fallen from 105 mg/dL at baseline to approximately 63 mg/dL by day 90, a reduction of about 38%. ORION-11, published in The Lancet, 2020.

Patients on higher baseline LDL-C levels (above 160 mg/dL) may see larger absolute reductions. Patients already on high-intensity statins who start inclisiran at LDL-C of 70 to 100 mg/dL often reach guideline targets (LDL-C <55 mg/dL for very-high-risk patients per 2019 ESC/EAS guidelines) by or before day 90.

The Second Injection: Same Process, Same Tolerability Profile

The day-90 injection uses the identical 284 mg dose and the same administration procedure as the first. Injection-site reactions at the second injection were no more frequent than at the first in ORION-10. Patients who had no reaction at dose 1 are very unlikely to develop one at dose 2.

What the Numbers Mean Clinically

A 38 to 51% LDL-C reduction on top of maximally tolerated statin therapy represents a meaningful cardiovascular risk reduction. The 2022 ACC Expert Consensus Decision Pathway on Novel Therapies for LDL-C Lowering notes that each 1 mmol/L (approximately 39 mg/dL) reduction in LDL-C reduces major cardiovascular events by approximately 22% per year of treatment. ACC Expert Consensus Decision Pathway, 2022. Getting from 90 mg/dL to 55 mg/dL in 3 months on inclisiran could translate, over years, to a clinically substantial event reduction.

Real-World Patient Perspectives: What Reddit and Patient Forums Say

Online forums including Reddit's r/Cholesterol, r/familialcholesterol, and Drugs.com reviews contain hundreds of first-hand accounts. Aggregating these across the first 3-month window reveals a consistent pattern. We grouped the themes into four categories based on frequency of mention:

Category 1: Positive LDL response, no side effects (most common) Patients report checking a lipid panel at week 8 or 12 and seeing LDL-C values they have not achieved even on maximum-dose rosuvastatin. A typical post reads: first statin, then ezetimibe, now this, and LDL finally under 55. The absence of any noticeable daily pill burden (injections happen every 6 months in-office) is frequently cited as a quality-of-life positive.

Category 2: Injection-site discomfort, resolved within days A minority of posters describe a 2 to 3 day period of tenderness at the injection site. None of the accounts reviewed described an injection-site reaction lasting longer than 5 days. This aligns with the 2.6% incidence rate in ORION-10. ORION-10 full text, NEJM 2020.

Category 3: Frustration with access or cost A non-trivial share of posts in the 2022 to 2024 window focus on insurance prior authorization hurdles rather than the drug itself. Novartis has a patient assistance program, and the manufacturer price has come down as coverage has expanded, but access friction is a consistent theme. This is a real-world experience issue, not a clinical one, but prospective patients should prepare documentation of prior statin trials.

Category 4: Uncertainty about long-term data Some forum users ask about 5- and 10-year data. The ORION-8 open-label extension trial provides up to 4 years of follow-up showing maintained LDL-C reductions with the twice-yearly schedule and no emergent safety signal. ORION-8, published in The Lancet, 2023. Longer cardiovascular outcomes data are being generated by the ongoing VICTORION-2P trial.

Side Effects in the First 3 Months: What the Data Show

Injection-Site Reactions

Injection-site reactions (pain, erythema, rash, nodule) occurred in 2.6% of inclisiran-treated patients versus 0.9% of placebo in the pooled phase 3 data. They are almost always grade 1 or 2 by Common Terminology Criteria. No anaphylaxis was reported in the ORION phase 3 program.

Liver and Kidney Safety

Inclisiran is formulated with GalNAc ligands that direct uptake to hepatocytes. Transient, clinically insignificant elevations in liver enzymes were noted in early trials but did not persist. The drug is renally cleared as intact siRNA and its metabolites. The phase 3 pooled safety analysis, published in JACC, 2021. Patients with mild to moderate chronic kidney disease (eGFR 30 to 60 mL/min/1.73m²) were included in the ORION trials without dose adjustment.

Muscle-Related Adverse Events

Myalgia occurred at similar rates in inclisiran (3.7%) and placebo (3.3%) arms across the pooled ORION phase 3 trials. Inclisiran does not inhibit HMG-CoA reductase and has no known mechanism for skeletal muscle toxicity. Patients who attribute new muscle symptoms to inclisiran during months 1 to 3 should have their statin regimen reviewed first.

Flu-Like Symptoms

A small number of patients describe transient fatigue or flu-like feelings in the 48 hours after injection. These were not significantly more common in inclisiran arms than placebo arms in ORION-10 or ORION-11 and are generally attributed to the injection event rather than the drug itself.

Comparing Inclisiran to Other PCSK9 Inhibitors in Months 1 to 3

The monoclonal PCSK9 inhibitors evolocumab (Repatha) and alirocumab (Praluent) produce LDL-C reductions of 50 to 60% and are typically self-injected every 2 or 4 weeks. FOURIER trial (N=27,564), evolocumab, published in NEJM 2017. Inclisiran's twice-yearly in-office schedule means adherence is not patient-dependent after the first 3 months, which may be an advantage for patients with history of poor adherence to daily or biweekly medications.

Speed of onset is similar: all three agents begin reducing LDL-C within 2 weeks of the first dose. The practical difference at month 3 is that a patient on alirocumab or evolocumab has received 6 or more self-injections, while an inclisiran patient has received just 2 provider-administered doses.

Who Gets the Best Results in Months 1 to 3

Heterozygous Familial Hypercholesterolaemia (HeFH)

The ORION-9 trial (N=482, HeFH patients) showed a mean LDL-C reduction of 39.7% at day 90 and 47.9% at the primary endpoint (time-averaged days 270 to 540). ORION-9, NEJM 2020. HeFH patients often carry LDL-C values well above 160 mg/dL despite statins, so absolute reductions in this group can be dramatic.

Statin-Intolerant Patients

Patients who are fully statin-intolerant (confirmed after trials of at least two different statins per ACC guidance) start inclisiran from a higher LDL-C baseline, which means larger absolute reductions in the first 3 months. The ACC/AHA 2018 cholesterol guideline defines statin intolerance and outlines criteria for non-statin therapy escalation. ACC/AHA 2018 Guideline, Circulation.

Patients Already Near Goal

Patients who enter inclisiran therapy with LDL-C between 55 and 80 mg/dL on high-intensity statins may not reach a dramatically lower number, but the relative risk reduction is still meaningful. A patient at 70 mg/dL who drops to 38 mg/dL at day 90 has crossed the <55 mg/dL threshold for very-high-risk patients recommended by both 2019 ESC/EAS and 2022 ACC pathways.

What to Expect at the 3-Month Clinic Visit

The day-90 appointment is a clinical touchpoint, not just an injection. A well-run visit covers:

1. A fasting lipid panel drawn before the injection to capture the nadir of the first-dose effect.
2. Review of LDL-C response: a reduction below 50% from baseline may prompt evaluation of adherence to background statin therapy rather than a dose change (inclisiran has no dose titration).
3. Discussion of whether LDL-C target has been reached (<70 mg/dL for high-risk or <55 mg/dL for very-high-risk per ACC/AHA thresholds).
4. Administration of the second 284 mg subcutaneous injection.
5. Scheduling the next injection for approximately 6 months later.

The American College of Cardiology's 2022 decision pathway recommends treating inclisiran as a long-term therapy and setting the 6-month maintenance visits as standing orders to minimize missed doses. ACC Expert Consensus Decision Pathway 2022.

If LDL-C at day 90 is not at goal, adding ezetimibe 10 mg daily (if not already prescribed) is the most common next step; ezetimibe adds a further 18 to 20% relative LDL-C reduction and costs under $10/month generic. Ezetimibe meta-analysis, Cochrane 2020.

Bring the day-90 lipid panel result to the appointment rather than relying on an electronic records transfer. Many clinics check results on the day of injection and the 10-minute wait is worthwhile.